Details

Targeting TAK1 : evolution of inhibitors, challenges, and future directions
ID Strašek Benedik, Nika (Author), ID Proj, Matic (Author), ID Steinebach, Christian (Author), ID Sova, Matej (Author), ID Sosič, Izidor (Author)

.pdfPDF - Presentation file, Download (3,08 MB)
MD5: 0A815DB59FCA00EC91E680FEC4A66C24
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0163725825000221 This link opens in a new window

Abstract
The increasing incidence of inflammatory and malignant diseases signifies the need to develop first-in-class drugs with novel mechanisms of action. In this respect, the transforming growth factor (TGF)-β-activated kinase 1 (TAK1), an essential part of several signaling pathways, is considered relevant and promising. This manuscript provides a brief overview of the signal transduction orchestrated by TAK1 within these pathways, followed by an in-depth and thorough analysis of the chemical matter demonstrated to inhibit this kinase. Special attention is given to the selectivity profiling of inhibitors, as well as to the outcomes of their biological characterization. Because published TAK1 inhibitors differ significantly in their kinome selectivity, active-site binding, and biological activity, we hope that this review will allow a judicial estimation of their quality and usefulness for TAK1-addressing assays. Our thoughts on the perspectives and possible developments of the field are also provided to assist scientists who are involved in the design and development of TAK1-targeting modulators.

Language:English
Keywords:transforming growth factor-β-activated kinase 1, inhibitors, inflammation, tumor necrosis factor, signaling pathways, structure-activity relationship
Work type:Article
Typology:1.02 - Review Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:20 str.
Numbering:Vol. 267, art. 108810
PID:20.500.12556/RUL-167118 This link opens in a new window
UDC:615.4:54
ISSN on article:1879-016X
DOI:10.1016/j.pharmthera.2025.108810 This link opens in a new window
COBISS.SI-ID:224969475 This link opens in a new window
Publication date in RUL:10.02.2025
Views:332
Downloads:90
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmacology & therapeutics
Shortened title:Pharmacol. ther.
Publisher:Elsevier
ISSN:1879-016X
COBISS.SI-ID:72613891 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:transformacijski rastni faktor-β-aktivirana kinaza 1, inhibitorji, vnetje, faktor tumorske nekroze, signalne poti, razmerje struktura-aktivnost, farmacevtska kemija

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:N1-0331
Name:Dvojni udarec NF-κB signalni poti: razvoj razgrajevalcev proteinov TAK1 in IKKβ za zdravljenje z vnetjem povezanih bolezni

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young researchers

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back